keyword
MENU ▼
Read by QxMD icon Read
search

Ulcerative colitis tnf

keyword
https://www.readbyqxmd.com/read/28230558/risk-for-overall-infection-with-anti-tnf-and-anti-integrin-agents-used-in-ibd-a-systematic-review-and-meta-analysis
#1
Eric D Shah, Jeremy P Farida, Corey A Siegel, Kelly Chong, Gil Y Melmed
BACKGROUND: The overall risk for infection with contemporary biological agents in treating Crohn's disease (CD) and ulcerative colitis (UC) has not been systematically assessed. METHODS: We performed a PubMed and Cochrane database literature search to evaluate randomized, placebo-controlled trials of biologics in treating UC and CD. Meta-analysis was performed using a DerSimonian and Laird random effects model. We determined relative risk (RR) of harm against placebo; number needed to harm (NNH) was reported when appropriate...
February 22, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28223944/il-1%C3%AE-induced-downregulation-of-the-multifunctional-pdz-adaptor-pdzk1-is-attenuated-by-erk-inhibition-rxr%C3%AE-or-ppar%C3%AE-stimulation-in-enterocytes
#2
Min Luo, Sunil Yeruva, Yongjian Liu, Giriprakash Chodisetti, Brigitte Riederer, Manoj B Menon, Keisuke Tachibana, Takefumi Doi, Ursula E Seidler
Background: The PDZ adaptor protein PDZK1 modulates the membrane expression and function of a variety of intestinal receptors and ion/nutrient transporters. Its expression is strongly decreased in inflamed intestinal mucosa of mice and IBD patients. Aim and Methods: We investigated whether the inflammation-associated PDZK1 downregulation is a direct consequence of proinflammatory cytokine release by treating intestinal Caco-2BBE cells with TNF-α, IFN-γ, and IL-1β, and analysing PDZK1 promotor activity, mRNA and protein expression...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28221250/factors-associated-with-discontinuation-of-anti-tnf-inhibitors-among-persons-with-ibd-a-population-based-analysis
#3
Laura E Targownik, Aruni Tennakoon, Stella Leung, Lisa M Lix, Zoann Nugent, Harminder Singh, Charles N Bernstein
INTRODUCTION: Antitumor necrosis factor (anti-TNF) medications are known to be highly efficacious in persons with moderate-to-severe inflammatory bowel disease (IBD). There is a paucity of data from population-based sources to elucidate persistence with these medications in the general population of IBD. Discontinuation of anti-TNF therapy is a marker of lack of effectiveness, intolerance, and patient/physician practice preferences. METHODS: We identified all persons with IBD in Manitoba who were dispensed infliximab (IFX) and adalimumab (ADA) between 2001 and 2014...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28219902/ndr1-protein-kinase-promotes-il-17-and-tnf-%C3%AE-mediated-inflammation-by-competitively-binding-traf3
#4
Chunmei Ma, Wenlong Lin, Zhiyong Liu, Wei Tang, Rahul Gautam, Hui Li, Youcun Qian, He Huang, Xiaojian Wang
Interleukin 17 (IL-17) is an important inducer of tissue inflammation and is involved in numerous autoimmune diseases. However, how its signal transduction is regulated is not well understood. Here, we report that nuclear Dbf2-related kinase 1 (NDR1) functions as a positive regulator of IL-17 signal transduction and IL-17-induced inflammation. NDR1 deficiency or knockdown inhibits the IL-17-induced phosphorylation of p38, ERK1/2, and p65 and the expression of chemokines and cytokines, whereas the overexpression of NDR1 promotes IL-17-induced signaling independent of its kinase activity...
February 20, 2017: EMBO Reports
https://www.readbyqxmd.com/read/28210268/protective-effect-of-daikenchuto-on-dextran-sulfate-sodium-induced-colitis-in-mice
#5
Takaharu Matsunaga, Shinichi Hashimoto, Naoki Yamamoto, Ryo Kawasato, Tomohiro Shirasawa, Atsushi Goto, Koichi Fujisawa, Taro Takami, Takeshi Okamoto, Jun Nishikawa, Isao Sakaida
Aim. To investigate the effect of daikenchuto (TJ-100; DKT) for ulcerative colitis (UC) model mouse and assess its anti-inflammatory mechanisms. Methods. We evaluated the effects of DKT on dextran sulfate sodium- (DSS-) induced experimental colitis. First, we assessed the short-term effects of DKT using two groups: 5% DSS group and 5% DSS with DKT group. Colon length; histological scores; and interleukin- (IL-) 10, IL-1β, and tumor necrosis factor-α mRNA expression profiles were analyzed using real-time PCR...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28207474/risk-of-colectomy-in-patients-with-pediatric-onset-ulcerative-colitis
#6
Firas Rinawi, Amit Assa, Rami Eliakim, Yael Mozer Glassberg, Vered Nachmias Friedler, Yaron Niv, Yoram Rosenbach, Ari Silbermintz, Noam Zevit, Raanan Shamir
OBJECTIVES: Data describing the incidence and risk factors for colectomy in pediatric ulcerative colitis (UC) is inconsistent. Our aim was to describe the colectomy rate and to identify risk factors associated with colectomy in a large cohort of children with UC with long term follow up. METHODS: We performed a retrospective chart review of pediatric UC cases that were diagnosed at Schneider Children's Medical Center of Israel between 1981 to 2013. Potential predictors for colectomy including age at diagnosis, gender, disease extent, severity indices and different therapeutic regimens during disease course were assessed...
February 15, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28204866/vedolizumab-treatment-for-immune-checkpoint-inhibitor-induced-enterocolitis
#7
Viktoria Bergqvist, Erik Hertervig, Peter Gedeon, Marija Kopljar, Håkan Griph, Sara Kinhult, Ana Carneiro, Jan Marsal
Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death protein-1 (PD-1) antibodies], improve survival in several cancer types. Since inhibition of CTLA-4 or PD-1 leads to non-selective activation of the immune system, immune-related adverse events (irAEs) are frequent. Enterocolitis is a common irAE, currently managed with corticosteroids and, if necessary, anti-tumor necrosis factor-α therapy...
February 15, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28191667/metastatic-recurrence-of-17-years-relapse-free-melanoma-during-anti-tnfa-therapy
#8
Ioana Cosgarea, Andreas Körber, Dorothee Dill, Dirk Schadendorf, Selma Ugurel
Tumor-necrosis-factor-alpha (TNFa) is an innate cytokine involved in regulating inflammation, immunity, tumorigenesis, and apoptosis. TNFa inhibitors became a powerful tool in the treatment of auto-immune inflammatory diseases such as Crohn's disease, ulcerative colitis, rheumatoid arthritis and psoriasis. Known side effects of TNFa inhibitors range from infections to malignancies [1]. We report a male patient who was in 1998 at age 36 diagnosed with amelanotic melanoma of the leg, Breslow thickness 11.0 mm, no ulceration...
February 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28191024/recent-trends-in-pharmacological-activity-of-alkaloids-in-animal-colitis-potential-use-for-inflammatory-bowel-disease
#9
REVIEW
Ana Cristina Alves de Almeida, Felipe Meira de-Faria, Ricardo José Dunder, Luis Paulo Bognoni Manzo, Alba Regina Monteiro Souza-Brito, Anderson Luiz-Ferreira
Inflammatory bowel disease (IBD) is a chronic and disrupted inflammation of the gastrointestinal tract. IBD have two main conditions, Crohn's disease and ulcerative colitis, and have been extensively investigated in recent years. Antibiotics derived from salicylates, steroids, immunosuppressors, and anti-TNF therapy are part of the therapeutic arsenal for IBD. However, very often patients stop responding to treatments over the time. In this context, searching for alternative agents is crucial for IBD clinical management...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28188801/astragalus-polysaccharides-protect-against-dextran-sulfate-sodium-induced-colitis-by-inhibiting-nf-%C3%AE%C2%BA%C3%B0-activation
#10
Jun Lv, Yahong Zhang, Zhiqiang Tian, Fang Liu, Ying Shi, Yao Liu, Peiyuan Xia
Astragalus polysaccharide (APS) is a bioactive extract of Astragalus membranaceus (AM), which possess a wide range of medicinal benefits, including anti-inflammatory, anti-oxidative, anti-tumor and anti-diabetic effects. The present work evaluated the therapeutic effect of APS and its potential mechanisms in a mouse model of dextran sulfate sodium (DSS)-induced colitis. The APS treatment led to significant improvements in colitis disease activity index (DAI) and histological scores, as well as significantly increased weight and colon length in mice as compared to the control group...
February 7, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28178003/efficacy-and-safety-of-vedolizumab-for-induction-of-remission-in-inflammatory-bowel-disease-the-israeli-real-world-experience
#11
Uri Kopylov, Yulia Ron, Irit Avni-Biron, Benjamin Koslowsky, Matti Waterman, Saleh Daher, Bella Ungar, Henit Yanai, Nitsan Maharshak, Ofer Ben-Bassat, Lev Lichtenstein, Ariella Bar-Gil Shitrit, Eran Israeli, Doron Schwartz, Eran Zittan, Rami Eliakim, Yehuda Chowers, Shomron Ben-Horin, Iris Dotan
BACKGROUND: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). The aim of this study was to examine the "real world" efficacy and safety of VDZ in a large national patient cohort. METHODS: Patients with inflammatory bowel disease treated with VDZ were prospectively followed for 14 weeks. Patients who completed the induction protocol (week 0/2/6/14) or discontinued the treatment before week 14 for adverse events (AEs) or primary nonresponse were included...
February 7, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28175184/p628-anti-tnf-therapy-in-refractory-pouchitis-and-crohn-s-disease-like-complications-of-the-pouch-after-ileal-pouch-anal-anastomosis-following-colectomy-for-ulcerative-colitis-a-systematic-review-and-meta-analysis
#12
M Huguet, B Pereira, M Goutte, F Goutorbe, C Allimant, M Reymond, G Bommelaer, A Buisson
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175106/p491-comparison-of-the-durability-of-response-to-subcutaneous-anti-tnf-therapy-between-ulcerative-colitis-and-crohn-s-disease
#13
G Mellotte, C McShane, J O'Connell, S Mc Kiernan, F Mac Carthy, D Kevans
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28173060/n816-anti-tnf-therapy-improves-the-quality-of-life-in-patients-with-ulcerative-colitis
#14
R P L Silva, J P Baima, G C Bissoli, E Farinelli, C F Sibia, J R Barros, R B Biondi, F L Renosto, R S Hossne, L Y Sassaki
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172971/p498-emerging-role-of-the-il-33-st2-axis-in-predicting-mucosal-response-to-anti-tnf-therapy-in-ulcerative-colitis
#15
L R Lopetuso, V Petito, C Graziani, D Scannone, F Scaldaferri, T T Pizarro, A Gasbarrini
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172946/p654-mucosal-healing-with-a-second-anti-tnf-%C3%AE-in-patients-with-ulcerative-colitis-after-the-failure-of-the-previous-anti-tnf-%C3%AE-treatment
#16
A Papa, D Pugliese, F D'Aversa, I De Vitis, R Landi, L Guidi, C Felice, V Gerardi, A Armuzzi, A Gasbarrini, G L Rapaccini
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172903/p388-risk-of-relapse-in-ulcerative-colitis-patients-in-clinical-remission-with-combination-therapy-anti-tnf-and-azathioprine-after-immunomodulator-discontinuation
#17
C Mihai, M Dranga, O Gavrilescu, I Ungureanu, A Didita, A M Chiosa, A Savin, I Popa, R Popa, O Jigaranu, C Cijevschi-Prelipcean
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172676/p227-outcomes-of-anti-tnf-versus-vedolizumab-therapy-for-ulcerative-colitis-the-leeds-experience
#18
M V Lenti, A Johnston, A O'Connor, C Selinger, A C Ford, P J Hamlin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28172507/p395-etrolizumab-demonstrated-no-difference-among-doses-in-symptomatic-and-endoscopic-based-evaluation-of-remission-in-anti-tnf-%C3%AE-na%C3%A3-ve-patients-in-a-post-hoc-analysis-of-the-phase-2-ulcerative-colitis-trial-eucalyptus
#19
W J Sandborn, S Schreiber, M T Tang, A R Tatro, Y S Oh, R Maciuca
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28164724/jak-inhibition-in-inflammatory-bowel-disease
#20
Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet
Current available treatments for inflammatory bowel disease (IBD) have some limitations and new options are needed. Several new molecules are being tested for the treatment of IBD and other immune-mediated inflammatory diseases. Among them, Janus kinase (JAK) inhibitors seem to have the lead, since tofacitinib has received regulatory approval in 2012 for the treatment of rheumatoid arthritis, and also it has shown a favorable risk-benefit ratio in phase 3 studies for ulcerative colitis, both in anti-TNF naïve and anti-TNF experienced patients...
February 4, 2017: Expert Review of Clinical Immunology
keyword
keyword
22393
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"